All In Biotech

Free tool

FAERS Monitor: Procysbi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 213491 or its brand name (Procysbi, Cysteamine Bitartrate). Reports on generic versions are filed under their own applications.

Reports

758

Serious

403

53% of reports

Hospitalization

226

Death reported

38

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • vomiting113
  • nausea104
  • eye irritation47
  • abdominal pain upper32
  • diarrhoea32
  • abdominal discomfort30
  • malaise28
  • death25
  • headache25
  • product dose omission issue23
  • illness22
  • amino acid level increased21
  • renal transplant21
  • pneumonia18
  • fatigue17

Reports by year received

View as table
YearReports
20132
201415
20163
201725
201893
2019102
2020116
202178
202238
202357
2024130
202560
202639

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,401 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
amino acid level increasedSignal21807.9526.615,671
renal transplantSignal21162.2106.33,188
eye irritationSignal4722.717.2954
vomitingSignal1136.75.6551
illnessSignal225.93.986
abdominal discomfortSignal305.03.592
abdominal pain upperSignal324.33.179
nauseaSignal1043.63.1205
product dose omission issueSignal232.21.514
malaise281.81.29
pneumonia181.51.03
diarrhoea321.41.03
headache251.10.80
death250.80.51
fatigue170.60.44

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.